Glaukos (NYSE:GKOS) Stock Rating Upgraded by Mizuho

Glaukos (NYSE:GKOS - Get Free Report) was upgraded by equities research analysts at Mizuho from a "neutral" rating to an "outperform" rating in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The brokerage currently has a $200.00 target price on the medical instruments supplier's stock, up from their previous target price of $140.00. Mizuho's price target suggests a potential upside of 58.69% from the stock's current price.

Several other research analysts have also recently weighed in on GKOS. Stephens raised shares of Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. Morgan Stanley cut shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price target on the stock. in a report on Monday, December 2nd. Citigroup raised shares of Glaukos from a "neutral" rating to a "buy" rating and increased their price target for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. UBS Group started coverage on shares of Glaukos in a report on Friday, December 6th. They issued a "buy" rating and a $182.00 price target on the stock. Finally, JPMorgan Chase & Co. increased their price target on shares of Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $163.25.

Glaukos Stock Performance

Shares of GKOS stock traded down $31.33 on Wednesday, reaching $126.03. The stock had a trading volume of 4,139,906 shares, compared to its average volume of 515,602. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm's 50-day moving average is $152.75 and its two-hundred day moving average is $139.41. The firm has a market capitalization of $6.95 billion, a price-to-earnings ratio of -43.91 and a beta of 1.04. Glaukos has a 12 month low of $83.90 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. On average, research analysts expect that Glaukos will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the transaction, the director now owns 32,336 shares of the company's stock, valued at $4,656,707.36. This represents a 5.82 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,744 shares of company stock worth $2,792,151. Corporate insiders own 6.40% of the company's stock.

Hedge Funds Weigh In On Glaukos

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Forum Financial Management LP bought a new position in shares of Glaukos during the fourth quarter valued at $211,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Glaukos by 20.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 162,326 shares of the medical instruments supplier's stock valued at $24,339,000 after acquiring an additional 27,889 shares during the last quarter. State of Wyoming raised its stake in shares of Glaukos by 2.3% during the fourth quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier's stock valued at $487,000 after acquiring an additional 72 shares during the last quarter. Thornburg Investment Management Inc. raised its stake in shares of Glaukos by 18.4% during the fourth quarter. Thornburg Investment Management Inc. now owns 45,583 shares of the medical instruments supplier's stock valued at $6,835,000 after acquiring an additional 7,072 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Glaukos by 44.0% during the fourth quarter. ProShare Advisors LLC now owns 14,869 shares of the medical instruments supplier's stock valued at $2,229,000 after acquiring an additional 4,542 shares during the last quarter. Institutional investors own 99.04% of the company's stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.